<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02959684</url>
  </required_header>
  <id_info>
    <org_study_id>PROunit-STRADA2016</org_study_id>
    <nct_id>NCT02959684</nct_id>
  </id_info>
  <brief_title>Strategic Screening for Infectious Diseases (Tuberculosis, HIV, HBV, HCV) Amongst Migrants in France</brief_title>
  <acronym>STRADA</acronym>
  <official_title>Strategic Screening for Infectious Diseases (Tuberculosis, HIV, HBV, HCV) Amongst Migrants in France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Paris 7 - Denis Diderot</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Paris 7 - Denis Diderot</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of a new screening for infectious diseases: tuberculosis, HIV, HBV
      and HCV, based on risk factors questionnaires (TB screen for tuberculosis and TROD screen for
      HIV and hepatitis) amongst a population of legal migrants during their mandatory medical
      check-up. This study aims for a global improvement of screening and care for migrants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In France, the prevalence of infectious diseases such as tuberculosis, HIV/HBV/HCV is high
      amongst migrants originating from certain countries, hence the official guidelines
      recommending targeted testing. The rapid testing devices (TROD) give immediate results and
      reduce missed opportunities. However their use is not yet widespread and migrant populations
      remain insufficiently tested. Regarding the UNAIDS 90-90-90 goal, France is failing the
      screening part of the treatment cascade, while 90% of patients are treated and have
      undetectable viral load. Risk scores based on the best known risk factors for these
      infections (HIV/HBV/HCV) have previously been developed. They have helped build a pilot of a
      new unique questionnaire: TROD screen. An electronic survey, called TB screen, was designed
      to screen for tuberculosis amongst asylum seekers in Switzerland and validated. This survey
      enables to detect signs of active tuberculosis and may replace the use of pulmonary
      radiography, thus reducing exposure to X-rays.

      It is a prospective multi-centric observational study validating screening tests for
      HIV/HBV/HCV in two phases:

        -  Phase 1: a risk score will be validated, including a qualitative study analyzing its
           acceptability

        -  Phase 2: its performance will be compared with that of a screening targeted based on the
           country of origin The phase 1 and phase 2 will include respectively 10.000 and 5000
           participants.

      For tuberculosis, the efficacy of the improved version of TB screen will be compared with a
      systematic radiography.

      Participation to this study will be voluntary and independent from the delivery of a
      residence permit. Participants will be informed of it and will systematically receive
      information about prevention of those infectious diseases.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the number of HIV, HBV or HCV positive patients identified in both arms of the screening strategy.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of tuberculosis patients identified through the modified TB screen questionnaire</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of HIV/HBV/HCV patients linked to care after being identified through TROD screen.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive value of the questionnaire TROD screen.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive value of the questionnaire TB screen.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness of the TROD screen questionnaire compared with a non-targeted screening, calculated in terms of cost per QALY (quality-adjusted life years) gained through this program</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">70000</enrollment>
  <condition>HIV</condition>
  <condition>Hepatitis C</condition>
  <condition>Hepatitis B</condition>
  <condition>Tuberculosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Migrants undergoing the routine immigration medical visit
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Migrants undergoing the routine medical visit

          -  Giving informed consent (oral consent)

        Exclusion Criteria:

          -  Asylum seekers

          -  Persons not understanding the questionnaire

          -  Persons aware of their HIV, HBV or HCV positive status
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Martin Duracinsky, MD, PhD</last_name>
    <phone>+33140275543</phone>
    <email>duracinsky.m@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frédérique Thonon, PhD</last_name>
    <phone>+33140275543</phone>
    <email>studymanager.proqol@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OFII Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique Thonon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OFII Cergy</name>
      <address>
        <city>Cergy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Lakhdari</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OFII Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>OFII Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique Thonon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OFII Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Lakhdari</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OFII Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique Thonon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OFII Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique Thonon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OFII Melun</name>
      <address>
        <city>Melun</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique Thonon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OFII Metz</name>
      <address>
        <city>Metz</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Lakhdari</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OFII Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique Thonon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OFII Montrouge</name>
      <address>
        <city>Montrouge</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique Thonon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OFII Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique Thonon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OFII Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique Thonon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OFII Orléans</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique Thonon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OFII Reims</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique Thonon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OFII Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique Thonon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OFII Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Lakhdari</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OFII Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique Thonon</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-07/synthese_recommandation__place_des_tests_rapides_dorientation_diagnostique_trod_hepatite_b_2016-07-21_13-56-32_782.pdf</url>
    <description>Guidelines for HBV rapid testing</description>
  </link>
  <link>
    <url>http://www.has-sante.fr/portail/upload/docs/application/pdf/2009-10/synthese_depistage_vih_volet_2_vfv_2009-10-21_16-48-3_460.pdf</url>
    <description>Guidelines for HIV testing</description>
  </link>
  <link>
    <url>http://www.has-sante.fr/portail/upload/docs/application/pdf/2014-05/place_des_trod_dans_la_strategie_de_depistage_de_vhc-_rapport.pdf</url>
    <description>Guidelines for HCV testing</description>
  </link>
  <reference>
    <citation>Meffre C, Le Strat Y, Delarocque-Astagneau E, Dubois F, Antona D, Lemasson JM, Warszawski J, Steinmetz J, Coste D, Meyer JF, Leiser S, Giordanella JP, Gueguen R, Desenclos JC. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol. 2010 Apr;82(4):546-55. doi: 10.1002/jmv.21734.</citation>
    <PMID>20166185</PMID>
  </reference>
  <reference>
    <citation>Schneeberger Geisler S, Helbling P, Zellweger JP, Altpeter ES. Screening for tuberculosis in asylum seekers: comparison of chest radiography with an interview-based system. Int J Tuberc Lung Dis. 2010 Nov;14(11):1388-94.</citation>
    <PMID>20937177</PMID>
  </reference>
  <reference>
    <citation>d'Almeida KW, Kierzek G, de Truchis P, Le Vu S, Pateron D, Renaud B, Semaille C, Bousquet V, Simon F, Guillemot D, Lert F, Crémieux AC; Emergency Department HIV-Screening Group. Modest public health impact of nontargeted human immunodeficiency virus screening in 29 emergency departments. Arch Intern Med. 2012 Jan 9;172(1):12-20. doi: 10.1001/archinternmed.2011.535. Epub 2011 Oct 24.</citation>
    <PMID>22025095</PMID>
  </reference>
  <reference>
    <citation>d'Almeida KW, Pateron D, Kierzek G, Renaud B, Semaille C, de Truchis P, Simon F, Leblanc J, Lert F, Le Vu S, Crémieux AC. Understanding providers' offering and patients' acceptance of HIV screening in emergency departments: a multilevel analysis. ANRS 95008, Paris, France. PLoS One. 2013 Apr 29;8(4):e62686. doi: 10.1371/journal.pone.0062686. Print 2013.</citation>
    <PMID>23638133</PMID>
  </reference>
  <reference>
    <citation>Bottero J, Boyd A, Gozlan J, Carrat F, Nau J, Pauti MD, Rougier H, Girard PM, Lacombe K. Simultaneous Human Immunodeficiency Virus-Hepatitis B-Hepatitis C Point-of-Care Tests Improve Outcomes in Linkage-to-Care: Results of a Randomized Control Trial in Persons Without Healthcare Coverage. Open Forum Infect Dis. 2015 Oct 26;2(4):ofv162. doi: 10.1093/ofid/ofv162. eCollection 2015 Dec.</citation>
    <PMID>26668814</PMID>
  </reference>
  <reference>
    <citation>Haukoos JS, Lyons MS, Lindsell CJ, Hopkins E, Bender B, Rothman RE, Hsieh YH, Maclaren LA, Thrun MW, Sasson C, Byyny RL. Derivation and validation of the Denver Human Immunodeficiency Virus (HIV) risk score for targeted HIV screening. Am J Epidemiol. 2012 Apr 15;175(8):838-46. doi: 10.1093/aje/kwr389. Epub 2012 Mar 19.</citation>
    <PMID>22431561</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2016</study_first_submitted>
  <study_first_submitted_qc>November 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2016</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Paris 7 - Denis Diderot</investigator_affiliation>
    <investigator_full_name>Dr Martin Duracinsky</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

